

3 **Supplementary material 1: Study Protocol**

4 I. **BACKGROUND**

5

6 ChRF is an ongoing respiratory condition characterized by progressive accumulation of
7 bicarbonate (HCO_3^-) in the venous system, feeling of breathlessness is the hallmark symptom of
8 ChRF which greatly compromises one's sleep quality, vitality, physical function and
9 psychosocial well-being.¹ As the ChRF prevalence increases drastically with age,² and is a
10 frequent cause of hospital admission,³ the associated disease burden would be on a high rise in
11 the coming decade of population aging.

12 Domiciliary non-invasive ventilation is a guideline-based management for ChRF. By
13 directing positive airway pressure via a facial mask to enhance inspiration, substantial evidence
14 has shown its positive effects on reducing hospital admission and mortality.⁴ Regarding COPD
15 patients with ChRF, nocturnal domiciliary NIV is prescribed to improve sleep time and
16 efficiency⁵, alleviate nocturnal hypoventilation and daytime hypercapnia⁶, reduce respiratory
17 muscle fatigue⁷ and improve respiratory mechanics^{6,8}. The benefits of domiciliary NIV in
18 chronic hypercapnic COPD patients including improvements in arterial blood gases, health-
19 related quality of life and mortality were evidenced in the results of some recent studies.⁹⁻¹⁵ For
20 instance, these benefits were demonstrated in the results of Kohnlein and colleagues' prospective
21 multi-center RCT¹² when moderate intensity NIV was used and patients with borderline
22 hypercapnia or low adherence were excluded. Domiciliary NIV was also shown to prolong the
23 time to readmission or death in patients with persistent hypercapnia after a COPD exacerbation,
24 when compared to oxygen alone.¹⁶

25 Adherence is an important factor affecting the clinical effectiveness of domiciliary NIV.
26 Previous studies indicated that NIV non-adherence posed major challenges to compromise the
27 therapeutic benefits on symptom control, HRQoL and even mortality,¹⁷⁻¹⁸ with an adherence
28 threshold defined as at least 4 hours/ day against improved respiratory function, gaseous
29 exchange and symptom control.¹⁹⁻²⁰ Lower percentage of days of domiciliary NIV use \leq 4
30 hours/day was correlated with increased hospitalization requiring acute NIV salvage ($P =$
31 0.042).²¹ Our team has previously identified various factors associated with domiciliary non-
32 adherence including machine noise ($P = 0.001$), difficulty in breathing ($P = 0.004$), conjunctivitis
33 ($P = 0.004$), excessively high air pressure ($P = 0.006$), sleep disturbance ($P = 0.017$) and


34 headache ($P = 0.029$).²¹ Other studies also identified air leakage, emotional responses along with
35 asynchronized breathing, fear of suffocation and treatment reliance, as well as social acceptance
36 as the hindering factors for domiciliary NIV use.²²⁻²³

37 Although adherence is fundamental to the efficacy of domiciliary NIV in patients with
38 CHRF, there are very few studies to improve the NIV adherence in patients with CHRF. There
39 are two qualitative studies²⁴⁻²⁵ on chronic hypercapnic patients' adherence to domiciliary NIV.
40 The qualitative findings of these studies indicate that patients or carers are in needs of
41 informational support such as understanding of nocturnal hypoventilation and its consequences²⁵,
42 technical and self-care support such as guidance on skin protection²⁵, guidance on ways to avoid
43 dry mouth²⁴, and psychosocial support such as acknowledging patients' emotional reactions²⁵,
44 promoting patients' confidence in the benefits of NIV, and supporting carers and family²⁴⁻²⁵. All
45 these care needs for promoting domiciliary NIV adherence also echo with the findings on factors
46 associated with non-adherence behaviors.²¹⁻²³ Up to our knowledge, there is only one trial used
47 cognitive-behavioral intervention to improve NIV adherence and the health outcomes.^{13/23}
48 However, the use of self-reported adherence was subject to social desirability and recall bias.
49 The reliance on clinical psychologist with intensive meetings may also compromise the fidelity
50 as evidence by the high attrition rate.^{13/23} As NIV requires long-term adherence, no intervention
51 component to address the motivational dimension of behavior change may also be a limitation.

52
53 Improving treatment adherence is associated with proactive behavioral changes. Behavioral
54 theories provide a good foundation to inform the care conceptualization to enhance treatment
55 adherence. Among these theories, the information-motivation-behavioral (IMB) skills model
56 may provide an especially relevant framework to address the complex determinants of poor NIV
57 adherence.¹⁴ According to Fisher et al.²⁶, the IMB skills model proposes that information,
58 motivation, and behavioral skills are the major determinants correlated with performance of
59 health-behavior. It also specifies a set of causal relationships among these constructs. The model
60 is presented in Figure 1. According to the model, it is necessary for to provide an individual with
61 comprehensive information to commit the desired health behaviors. Increasing one's personal
62 and social motivation is an essential pre-requisite to enable and sustain the behavioral changes.
63 Whereas personal motivation concerns with cultivating positive attitude towards the NIV use,
64 social motivation is about the ways to optimize their perceived social support and social

65 acceptance in treatment compliance. As for the behavioral component, the IMB skills model also
66 goes beyond empowering the clients with skills on managing the treatment required adherence
67 but also their self-efficacy and self-control on the behavioral changes. This emphasis would be
68 the most relevant to address the maladaptive emotional responses to NIV usage. In sum, the IMB
69 skills model highlights that the information and motivation constructs interact with each other to
70 directly and indirectly via the behavior skills construct to affect the performance of health-
71 behavior.

72
73



74

75 **eFigure 1. The Information-Motivation-Behavioral Skills Model of health behavior.**³⁷

76

77

78 The IMB skills model has been validated in empirical studies on the causal relationships
79 among its constructs and confirmed its predictive validity.²⁶⁻²⁸ Earlier studies confirmed its
80 applicability in patients with AIDS,²⁸ later studies further confirmed its applicability in smoking
81 cessation and patients with chronic health problems including cancer, type 2 diabetes, coronary
82 heart disease, and knee osteoarthritis²⁸⁻³¹. Regarding domiciliary NIV adherence in patients with
83 CHRF, the previous qualitative findings on the patients' needs of support are well aligned with
84 the information, motivation, and behavioral skill constructs of the IMB model.²⁴⁻²⁵ The effects of
85 intervention strategies based on IMB skills model for health behavior change were supported by
86 the results of a systematic review.²⁸ Varying with duration of intervention, the intervention
87 effects ranged from immediately after to one year post-intervention. Strategies for integrating
88 IMB skills model constructs in intervention included various educational materials and teaching
89 skills for providing information; counseling, motivational strategies and mobilize social support

90 at family level and beyond for increasing motivation; teaching objective skills and enhancing
91 self-efficacy for developing behavioral skills.²⁷⁻³¹

92 Our team conduct the first pilot RCT to develop and evaluate an intervention based on the
93 IMB skills model for promoting patients' adherence to inhalation therapy in COPD.³² This was
94 the first pilot RCT (N=30) which randomized the participants to receive the intervention based
95 on the IMB skills model or the usual care. The tested intervention consisted of a one-hour face-
96 to-face session for information provision, motivation enhancement and behavioral skill training.
97 A person-centered action plan was developed to optimize the self-care of inhalation therapy.
98 Two telephone follow-up visits were scheduled in the second and fourth weeks, with the purpose
99 to review the action plan implementation and provide informational and psychosocial support for
100 reinforcing adherence. The results supported the effectiveness of this four-week IMB model-
101 based intervention for improving inhalation adherence (β [95% CI] = 2.01[0.38, 3.63], $P = 0.015$)
102 and inhalation techniques (β [95% CI] = 15.57[0.385.73, 25.42], $P = 0.002$). Moreover, the
103 intervention was found feasible for application in the local clinical setting and was well accepted
104 by the patients.

105
106 The overall aim of this study is to extend the use of the IMB skill-based model to enhance the
107 adherence of domiciliary NIV and the health outcomes including venous bicarbonate (HCO_3^-),
108 patient-reported health outcomes and health service use.

109

110

111 **II. RESEARCH AIM & OBJECTIVES**

112

113 The overall aim of this study is to examine the effect of the IMB-NIV Program which
114 based on information motivation behavioral (IMB) skills model to improve the adherence of
115 domiciliary NIV and the health outcomes of patients with chronic hypercapnic respiratory failure
116 (CHRF). The primary outcome is the NIV adherence, which defined as the use of domiciliary
117 NIV for at least 4 hours per night for at least 70% of the days or a mean daily use of at least 5
118 hours per day. The secondary outcomes include venous (HCO_3^-), patient-reported health
119 outcomes (including sleep quality, health-related quality of life) and health service use
120 (unplanned hospital admissions related to hypercapnic respiratory failure and survival). All the

121 outcomes except venous (HCO_3^-) are measured at baseline, post-intervention, and 6th and 12th
122 month. The venous HCO_3^- are assessed up to the second post-test endpoint at 6th month.

123 .

124 III. **REASEARCH METHODS:**

125

126 1. **Study design**

127 It is a multi-site, assessor-blind, randomized controlled trial. The intervention group will receive
128 an IMB-NIV program while the control group will receive the usual care. The study will comply
129 with the Declaration of Helsinki.

130

131 2. **Subjects**

132 This study will recruit patients with CHRF, who are non-adherers to domiciliary NIV, from the
133 respiratory clinics of two regional hospitals in Hong Kong. The inclusion criteria include:
134 patients who are: (1) diagnosed with CHRF (i.e., $\text{PaCO}_2 \geq 7$ kPa of 52.5mmHg) for at least 4
135 weeks; (2) prescribed with domiciliary NIV for ≥ 4 weeks, and (3) non-adherer (i.e., used
136 domiciliary NIV for < 4 hours per night for $> 70\%$ of days or with a mean daily use < 5 hours
137 per day in the last 2 weeks). Patients with known psychiatric disorders except anxiety and
138 depression, disease limiting life expectancy ≥ 1 year, and active malignancy were excluded.

139

140 The effect size is estimated from our pilot study that IMB-NIV can improve treatment adherence
141 by almost 40% (IMB-NIV vs usual care: 70.6 vs 31.6) at 12-month endpoint.³³ We
142 conservatively assume an effect size of 25% between-group in treatment adherence with 45%
143 and 20% improvement in the IMB-NIV and usual care group respectively. Power analysis by
144 Pass 14.0 (NCSS, Kaysville, Utah) indicated 62 participants per group is needed to achieve 80%
145 power at 2-sided 95% confidence interval, allowing for 15% attrition. Permutated block
146 randomization using the block size of 4, 6, and 8 and computer-generated sequences for block
147 size and within-block group status assigned the participants to receive the IMB-NIV program or
148 usual care in an 1:1 ratio. A sequence of grouping identifiers (I & C) based on computer-
149 generated random codes will be prepared in advanced by an independent statistician. After
150 obtaining informed consent, group allocation of each participant will be assigned sequentially

151 according to his/her sequence of enrolment and the corresponding group identifier in the priori
152 prepared random grouping list. The participants will be blinded to their group allocation.

153

154

155 **3. Study intervention: The IMB-NIV Program**

156 The 6-week IMB-NIV Program adopted a hybrid approach including 1-hour face-to-face
157 home visit, two telephone follow-ups and one 30-minute clinic visit to increase the accessibility
158 to the CHRF patients who are more likely to have compromised activity tolerance. A telephone
159 consultation hotline during office hour is provided. The program was delivered by a registered
160 nurse who had received training in advanced respiratory care, and a multi-disciplinary team
161 including geriatricians and advanced practice nurses support the program development and
162 implementation.

163 The Program will be commenced with a home visit during which the nurse assesses the
164 participant's self-care needs (including information, motivation and behavioral skills) on CHRF
165 and NIV. Health education on self-care will be given in a way so that the participants'
166 misconception and ineffective illness behaviors. Information will be provided with assistance of
167 audio-visual materials, as appropriate. The information content includes knowledge of the
168 disease, knowledge of nocturnal hypoventilation and its consequences, the benefits of NIV, how
169 to operate and maintain the ventilator, what are and how to follow the NIV prescription, common
170 problems in using NIV, how to solve the problems, and the concomitant health consequences of
171 poor NIV adherence. This arrangement aims to motivate the followed participant-centered goal
172 settings and action planning to enhance NIV adherence. A nurse-patient partnership approach
173 will be used, together with various strategies for enhancing personal and social motivation
174 towards NIV adherence including establishment of rapport (e.g., acknowledging the patient's
175 experience and emotions towards the disease and use of domiciliary NIV), emphasizing the
176 benefits of domiciliary NIV, involving family to support the patient, individual counseling (e.g.,
177 encouraging the patient to express feelings, concerns and problems encountered, clarifying
178 misbeliefs and confront negative thoughts, working with the patient to identify possible
179 solutions, respecting and supporting the patient's choices in problem-solving), making agreement
180 on a goal-oriented action plan, providing positive reinforcement (e.g., review and praise for

181 achievements and mastery of skills in NIV adherence) and psychosocial support (e.g., active
 182 listening and therapeutic communication).
 183 Behavioral skill training on proper NIV handling and complication prevention will be provided
 184 with emphasis on technical skills for operating the ventilator at home environment, handling
 185 interface (e.g., reducing air leak) and ventilator maintenance, and self-care skills (e.g., skin and
 186 eye protection). Strategies will include verbal instructions, physical demonstration, return-
 187 demonstration, constructive feedback and positive reinforcement in conjunction with assistance
 188 of audio-visual materials. The visit will be closed with a brainstorming on anticipated barriers for
 189 goal attainment and the corresponding resolving methods are discussed. Family will be involved
 190 to support the patient if available and a telephone consultation hotline during office hour is
 191 given.

192 Two tele-visits were scheduled at 2nd and 4th week for goal monitoring and review.
 193 Further health counseling on barriers on NIV adherence and newly evolved self-care challenges
 194 were given. The program was ended with a follow-up clinic visit, with the aim to substantiate
 195 long-term behavioral changes to favor NIV adherence. Health communication was done in a way
 196 to support the participants to reflect on the changes in NIV self-care and the concomitant
 197 perceived health consequence. Positive reinforcement was given to highlight the prognostic
 198 benefits of optimal NIV adherence. Further behavioral skill training will be given as appropriate.
 199 Explicit methods to support longer-term motivation and effective self-care maintenance were
 200 discussed. The intervention content is presented in eTable 1.

201

202 **eTable1. Content of the IMB-NIV program**

203

<p>1st week Empowerment cycle 60-minute home visit</p>	<p><u>Person-centered assessment to identify patients' self-care practice on NIV management:</u></p> <ul style="list-style-type: none"> • Self-care for the CHRF and the respiratory disorders including symptom monitoring management, medication management, activity pacing and sleep-related self-care • The management of domiciliary NIV at home including technical operation of the NIV, strategies for self-monitoring and prevent complications. • Perceived function of NIV • Perceived benefits of NIV • Barriers for NIV adherence and resolving methods
--	--



Information giving: [offer an information booklet/ self-care cards]

Providing the patients with structure education on the following topic. The education is tailored to the patient's needs as identified in the above-mentioned assessment.:

- knowledge of the disease and nocturnal hypoventilation,
- awareness on relationship between NIV and prognosis;
- self-care for NIV with skill demonstration and return demonstration
- common problems in using NIV and resolving methods

NB. The information booklet and self-care card provided a more structured template so that the nurse can put down more person-centered information to the template to tailor the self-care information for the patients.



Highlight self-care deficit

Highlight the discrepancy between the optimal NIV care and patients' reported self-care. Based on the discrepancy in self-care, the nurse elaborates the corresponding detrimental health consequences. The purpose of this step is to increase the intrinsic motivation of the patients in making more proactive behavioral changes in managing the disease and NIV use. This step also increases the patients' readiness and preparedness to set goals to guide the behavioral changes on NIV adherence



Support self-care goal setting and action planning


Formulating short-and medium goals to enhance NIV self-care and adherence & action plan.

[provide log-book to monitor the level of goal attainment]



Resolve prominent concern for goal attainment:

Reviewing the goals and action plan with the patients. The nurse encourages the patients to think of any anticipated challenges and barriers which might affect the action plan implementation. The nurse will work with the patients to identify the potential resources to tackle the barriers, and to brainstorm how to mobilize such resource to support the action plan implementation and thereby the goal attainment. If necessary, the goals and action plan will be adjusted in order to optimize

	<p>its implementation feasibility. The nurse will also discuss any other concern about action plan implementation and provide the patient with resolving methods.</p> <p style="text-align: center;"></p> <p><u>Behavioral skill building</u> The nurse will revisit the skills of the patients in using the NIV including fitting the mask, checking for leakage, humidification, preventing and monitoring for skin pressure, positioning, operating the NIV machine, storage and care of the tubing and masks. Demonstration and return demonstration will be provided. Other self-care skills required for goal attainment such as breathing techniques, upper limb strengthening exercise, activity pacing, relaxation-based practice for emotional control will also be provided according to the actions planned for goal attainment.</p>
<p>2nd week 20-min telephone intervention.</p>	<p>Evaluate the action plan implementation and the level of goal attainment. Identify any barriers, and use a partnership approach to provide resolution. Provide health education and counseling to support the goal attainment. Adjust the goals if necessary.</p> <p>[Nursing documentation: telephone record]</p>
<p>4th week 20-min telephone intervention.</p>	<p>Monitor the level of goal attainment and action plan implementation Provide further health counseling and advice for the reported barriers and challenges in goal attainment. Goal adjustment as appropriate.</p> <p>[Nursing documentation: telephone record]</p>
<p>6th week 30-minute clinic visit</p>	<p>30-min face-to-face follow-up session at hospital/ at patient's home</p> <ul style="list-style-type: none"> - guided reflection on patient-reported change in NIV management over the past few weeks and the success in coping with challenges and barriers; - support the patients to identify associated perceived health-related changes, if any; - discuss challenges and methods to sustain the positive behavioral changes, if any. - discuss any shortcomings in self-care and advise on the resolving methods

204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233

4. **Study intervention: Usual Care**

The usual care included regular medical follow-up in the respiratory clinic by a medical consultant. A nursing team would support problem-shooting on using the domiciliary NIV and provided the health education accordingly. The IMB group received the same usual care during the medical follow-up. The participants in the IMB-NIV program will also receive the same usual care during the medical follow-up.

5. **Outcome measures**

All outcomes were collected at baseline, upon completion of the IMB-NIV (i.e, program exit at the 7th week), and at 3rd, 6th and 12th months. Another nurse without information about the participants' group status will collect the data. The primary outcome is the domiciliary NIV adherence and the secondary outcomes including sleep quality, health-related quality of life, and venous bicarbonate. Following are the outcome evaluation methods.

Domiciliary NIV adherence:

It is the primary outcome that the machine data will be retrieved. The records from the software fitted on the subject's NIV machine for the past two weeks will be reviewed to determine adherence or non-adherence, and assessed for the percentage of days with usage of at least 4 hours per night and the mean of daily use.

Sleep quality

The Chinese Pittsburgh Sleep Quality Index (CPSQI) will be used to assess the subject's sleep quality.³⁴ The CPSQI is a 19-item self-reported measures for assessing sleep quality over last month. Seven component scores including subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, sleep medication, and daytime dysfunction can be obtained from the items. The component scores range from 0 (no problem) to 3 (severe problem) and an overall score can be obtained by aggregating the component scores. The overall score range from 0 to 21 with a higher score indicating a poorer sleep quality. The validity and reliability of CPSQI have been confirmed in Chinese populations.³⁵⁻³⁷ The CPSQI has a

234 Cronbach's α coefficient 0.79 and a good test-retest reliability ($r = 0.79, P = 0.01$) for a 3-week
235 interval.³

236

237 Health-related quality of life (HRQoL)

238 The Chinese Severe Respiratory Insufficiency questionnaire (CSRI) will be used to assess the
239 participants' HRQoL.³⁸ The CSRI consists a total of 49 items for seven subscales (i.e.,
240 respiratory complaints, physical functioning, attendant symptoms and sleep, social relationships,
241 anxiety, psychological well-being, and social functioning). Each item is rated on a 5-point Likert
242 scale ranging from 1=completely untrue to 5=always true. Subscale scores can be summed up to
243 obtain a total score. After transformation of raw scores, subscale and total scale scores range 0-
244 100. It has been validated in Chinese COPD patients with hypercapnia and the reported
245 Cronbach's α coefficients were all above 0.7.³⁸

246

247 Venous bicarbonate (HCO_3^-)

248 The subject's venous blood sample of 3-5 ml will be collected for laboratory tests of venous
249 HCO_3^- which is considered as less invasive and a reliable estimation for level of hypercapnia.³⁹⁻⁴⁰
250 The normal range for venous HCO_3^- is 23-29 mmol/L.

251

252 Hospital admissions and survival rate

253 The subject's number of emergence room and unplanned hospital admissions related to
254 hypercapnic respiratory failure at 7th week, 3-, 6-, and 12 months after baseline and survival
255 information at 7th week, 3-, 6-, and 12 months after baseline will be obtained from the subject's
256 medical record via the Clinical Management System (CMS) of Hospital Authority.

257

258 **6. Data collection procedure**

259 Patients will be recruited by the RA from the respiratory clinics, according to subject
260 inclusion and exclusion criteria. The RA will explain to eligible patients the purpose of the study,
261 their commitment and their right to withdraw at any time. Formal written consent will be
262 obtained from patients. Then the RA will collect the participant's socio-demographic and clinical
263 characteristics, and baseline data (i.e., domiciliary NIV adherence in the past two weeks, CPSQI,
264 CSRI, and number of unplanned hospital admissions related to hypercapnic respiratory failure in

265 the past 6 months). While a doctor of the respiratory team will prescribe collection of venous
266 HCO_3^- for the hospital phlebotomist to collect venous blood sample, the RA will collect the
267 participant's result of venous HCO_3^- from the CMS of the hospital. After collection of baseline
268 data, participants will be randomly assigned to intervention or control group.

269 The RA will contact the participant by phone to arrange collection of post-interventional data
270 when the time is approaching. The RA will collect post-interventional data (i.e., domiciliary NIV
271 adherence in the past two weeks, CPSQI, and CSRI) at the patient's home according to the study
272 timeline. A doctor of the respiratory team will prescribe collection of venous HCO_3^- again for the
273 hospital phlebotomist to collect venous blood sample with the patient in hospital at 3 months and
274 6 months after baseline. The RA will retrieve the patient's venous HCO_3^- result accordingly;
275 number of unplanned hospital admissions related to hypercapnic respiratory failure at 7th week,
276 3, 6, and 12 months after baseline;, and survival information from the CMS of the hospital at 7th
277 week, 3, 6, and 12 months after baseline.

278

279 **7. Data analysis**

280 The IBM SPSS 29.0 (IBM Corp., Armonk, NY) will be used for data analysis. Data coding will
281 be carried out before data entry. The data will be double-entered for validation and analyzed on
282 an intention-to-treat basis. Data cleansing will be carried out to eliminate data entry errors.
283 Normality of continuous data will be assessed on the basis of skewness and kurtosis statistics and
284 normal probability plot. Suitable transformation will be made on skewed variables if needed.
285 Descriptive statistics including frequency, percentage, mean, median, range, standard deviation
286 and inter-quartile range will be used to summarize socio-demographic and clinical characteristics
287 of the participants and their health outcome measurements (i.e., adherence data, the venous
288 HCO_3^- , CPSQI, CSRI, number of unplanned hospital admissions, and survival rates).
289 Homogeneity of socio-demographic and clinical data between the intervention and control
290 groups will be assessed by using chi-square, Fisher's exact or independent t tests, as appropriate,
291 with adjustment for potential confounders (i.e. baseline group difference in clinical-demographic
292 characteristics at $p < 0.25$ (two-sided)).
293 Generalized estimating equations (GEE) models will be used to compare the primary (NIV
294 adherence) and secondary outcomes (the venous HCO_3^- , CPSQI, CSRI) across time points
295 between the two groups. GEE model can account for intra-correlated repeated measures data and

296 be applicable for various kinds of outcome variables with the use of suitably chosen link
297 function.^{9/41} Furthermore, such model can produce unbiased estimates even in the presence of
298 missing data, provided the data are missing at completely random.⁴¹ If the data is not missing at
299 random as indicated by a statistical significant results of the Little's Missing Completely at
300 Random test (MCAR), multiple imputation method will be used to impute missing data, using all
301 available baseline characteristics as covariable. Predictive mean matching approach which relies
302 less on the parametric assumptions of the imputation models will be used.⁴² A dummy variable
303 (group) will be assigned to represent the intervention group with the control group as reference.
304 Other dummy variables (Time) representing time differences, the first post-test endpoint (T1),
305 second post-test endpoint (T2 at the 6th month) and the third post-test endpoint (T3 at the 12th
306 month) will be set to correspond to T1, T2 and T3 respectively, with the baseline T0 as the
307 reference. The interaction terms of the time-point dummy variables and group (group*T1,
308 group*T2 and group*T3) will be included in the GEE model to assess the differential changes of
309 each outcome at T1, T2, and/or T3 relative to T0 between the two groups. Adjusted mean
310 difference and the 95% confidence interval of the differential change over time between the two
311 study groups were reported (with the baseline as the reference) and the Cohen d was computed to
312 indicate the effect size of the between group difference in the change from the baseline. Negative
313 binomial regression identified the between-group differences in ER attendance and the hospital
314 admissions because these data may be over-dispersed in the sample. Cox proportional hazards
315 regression analysis was performed to compare the between-group difference in the time to event
316 (i.e. unplanned time to hospital readmission and mortality). All statistical tests involved will be
317 2-sided with level of significance set at 0.05.

318

319

320 **IV. ETHICAL CONSIDERATIONS**

321

322 Ethical approvals for the study from Research Ethics Committee from the Hospital Authority
323 (Kowloon Central/Kowloon East/ Hong Kong West region) before the commencement of the
324 study. The participation is voluntary and written informed consent will be obtained from the
325 participants. All the data collection is anonymous and the confidentiality will be maintained.
326 Only the research team will have access to the data.

327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357

V. REFERENCES

1. Shah NM, Steier J, Hart N, *et al.* Effects of non-invasive ventilation on sleep in chronic hypercapnic respiratory failure. *Thorax*, 2024,**79**:281-288.
2. Chung Y, Garden FL, Marks GB, Vedam H. Population prevalence of hypercapnic respiratory failure from any cause. *Am J Respiratory and Critical Care Medicine*, 2022: 205(8): 968-969.
3. Meservey AJ, Burton MC, Priest J, Teneback CC, Dixon AE. Risk of Readmission and Mortality Following Hospitalization with Hypercapnic Respiratory Failure. *Lung*, 2020,198(1):121-134.
4. Raveling T, Vonk J, Struik FM, *et al.*. Chronic non-invasive ventilation for chronic obstructive pulmonary disease. *Cochrane Database System Review*, 2021, 8:CD002878. 10.1002/14651858.CD002878.
5. Meecham Jones DJ, Paul EA, Jones PW, Wedzicha JA. Nasal pressure support ventilation plus oxygen compared with oxygen therapy alone in hypercapnic COPD. *Am J Respir Crit Care Med* 1995; 152: 538-44.
6. Elliott MW, Mulvey DA, Moxham J, Green M, Branthwaite MA. Domiciliary nocturnal nasal intermittent positive pressure ventilation in COPD: mechanisms underlying changes in arterial blood gas tensions. *Eur Respir J* 1991; 4: 1044-52.
7. Ambrosino N, Montagna T, Nava S, Negri A, Brega S, Fracchia C, *et al*Zocchi L, Rampulla C. Short term effect of intermittent negative pressure ventilation in COPD patients with respiratory failure. *Eur Respir J* 1990; 3: 502-8.
8. Duiverman ML, Wempe JB, Bladder G, Vonk JM, Zijlstra JG, Kerstjens HA, Wijkstra PJ. Two-year home-based nocturnal noninvasive ventilation added to rehabilitation in chronic obstructive pulmonary disease patients: a randomized controlled trial. *Respir Res* 2011; 12: 112.
9. Suraj KP, Jyothi E, Rakhi R. Role of domiciliary noninvasive ventilation in chronic obstructive pulmonary disease patients requiring repeated admissions with acute type II respiratory failure: A prospective cohort study. *Indian J Crit Care Med* 2018; 22(6). doi: 10.4103/ijccm.IJCCM_61_18

- 358 10. Blankenburg T, Benthin C, Pohl S, Bramer A, Kalbitz F, Lautenschlager C, Schutte W.
359 Survival of hypercapnic patients with COPD and obesity hypoventilation syndrome
360 treated with high intensity non-invasive ventilation in the daily routine care. *The Open*
361 *Respir Med J* 2017; 11: 31-40.
- 362 11. Duiverman ML, Windisch W, Storre JH, Wijkstra PJ. The role of NIV in chronic
363 hypercapnic COPD following an acute exacerbation: the importance of patient selection?
364 *Thorax* 2016; 10(2): 149-57. doi:10.1177/1753465815624645
- 365 12. Kohnlein T, Windisch W, Kohler D, Drabik A, Geiseler J, Hartl S, Karg O, Laier-
366 Groneveld G, Nava S, Schonhofer B, Schucher B, Wegscheider K, Criece CP, Welte T.
367 Noninvasive positive pressure ventilation for the treatment of severe stable chronic
368 obstructive pulmonary disease: a prospective, multicentre, randomised, controlled clinical
369 trial. *Lancet Respir Med* 2014; 2: 698–705.
- 370 13. Dreher M, Storre JH, Schmoor C, Windisch W. High-intensity versus low-intensity non-
371 invasive ventilation in patients with stable hypercapnic COPD: a randomised crossover
372 trial. *Thorax* 2010; 65: 303-8.
- 373 14. McEvoy RD, Pierce RJ, Hillman D, Esterman A, Ellis EE, Catcheside PG, O'Donoghue
374 FJ, Barnes DJ, Grunstein RR. Nocturnal non-invasive nasal ventilation in stable
375 hypercapnic COPD: a randomised controlled trial. *Thorax* 2009; 64: 561-6.
376 doi:10.1136/thx.2008.108274
- 377 15. Altintas N. Update: Non-invasive positive pressure ventilation in chronic respiratory
378 failure due to COPD. *COPD* 2016; 13: 110-21.
- 379 16. Murphy PB, Rehal S, Arbane G, Bourke S, Calverley PMA, Crook AM, et al. Effect of
380 home noninvasive ventilation with oxygen therapy vs oxygen therapy alone on hospital
381 readmission or death after an acute COPD exacerbation: A randomized clinical trial.
382 *JAMA* 2017, 317(21): 2177-86. doi: 10.1001/jama.2017.4451
- 383 17. Schwarz EI, Mackie M, Weston N, Tincknell L, Beghal G, Cheng MCF, et al. Time-to-
384 death in chronic respiratory failure on home mechanical ventilation: a cohort study.
385 *Respiratory Medicine*, 2020, 162:105877. 7.
- 386 18. Patout M, Lhuillier E, Kaltsakas G, Benattia A, Dupuis J, Arbane G, et al. Long-term
387 survival following initiation of home non-invasive ventilation: a European study. *Thorax*,
388 2020;75(11):965-973.

- 389 19. Mokhlesi B, Tulaimat A, Evans AT, Wang Y, Itani AA, Hassaballa HA, et al. Impact of
390 adherence with positive airway pressure therapy on hypercapnia in obstructive sleep
391 apnea. *Journal of Clinical Sleep Medicine*, 2006, 2 (1):57-62.
- 392 20. Masa JF, Corral J, Alonso ML, Ordax E, Troncoso MF, Gonzalez M, et al. Efficacy of
393 different treatment alternatives for obesity hypoventilation syndrome. *Pickwick Study*.
394 *American Journal of Respiratory and Critical Care Medicine*, 2015, 192(1):86-95.
- 395 21. Cheng S, Chan VL, Chu CM. Compliance with home non-invasive ventilation.
396 *Respirology* 2012; 17: 735-6.
- 397 22. Beckert, L., Wiseman, R., Pitama, S., and Landers, A. What can we learn from patients to
398 improve their non-invasive ventilation experience? ‘It was unpleasant; if I was offered it
399 again, I would do what I was told.’. *BMJ Support. Palliative Care*, 2020, 10:e7. doi:
400 10.1136/bmjspcare-2016-001151
- 401 23. Volpato E, Banfi PI and Pagnini F. Acceptance and adherence to non-invasive positive
402 pressure ventilation in people with chronic obstructive pulmonary disease: a grounded
403 theory study. *Frontier. Psychology*, 2023, 14:1134718.
- 404 24. Gale NK, Jawad M, Dave C, Turner AM. Adapting to domiciliary non-invasive
405 ventilation in chronic obstructive pulmonary disease: A qualitative interview study.
406 *Palliative Medicine* 2014; Dec: 1-10. doi: 10.1177/0269216314558327
- 407 25. Ennis J, Rohde K, Chaput J, Buchholz A, Katz SL. Facilitators and Barriers to
408 Noninvasive Ventilation Adherence in Youth with Nocturnal Hypoventilation Secondary
409 to Obesity or Neuromuscular Disease. *J Clin Sleep Med* 2015; 11(12): 1409 –16.
- 410 26. Fisher WA, Fisher JD, Harman J. The Information-Motivation-Behavioral Skills Model:
411 A general social psychological approach to understanding and promoting health behavior.
412 In Suls, Wallston (Eds.), *Social psychological foundations of health and illness*, 82-106.
413 Cornwall, UK: Blackwell Publishing Ltd, 2003.
- 414 27. Chang SJ, Choi S, Kim S, Song M. Intervention strategies based on Information-
415 Motivation-Behavioral Skills Model for health behavior change: a systematic review.
416 *Asian Nurs Res* 2014; 8: 172-81.
- 417 28. Mayberry LS, Osborn CY. Empirical validation of the Information-Motivation-
418 Behavioral Skills Model of diabetes medication adherence: A framework for
419 intervention. *Diabetes Care* 2014; doi:10.2337/dc13-1828.

- 420 29. Cooperman NA, Richter KP, Bernstein SL, Steinberg ML, Williams JM. Determining
421 smoking cessation related information, motivation, and behavioral skills among opiate
422 dependent smokers in methadone treatment. *Substance Use and Misuse* 2015; 50: 566-
423 581.
- 424 30. Kim YI, Park JS. Development and Evaluation of a Joint Health Self-management
425 Program for the Elderly with Knee Osteoarthritis in Communities: Applying the IMB
426 Model. *J Korean Acad Community Health Nurs* 2017; 28(1): 55-68.
- 427 31. Nelson LA, Wallston KA, Kripalani S, LeSturgeon LM, Williamson SE, Mayberry LS.
428 Assessing barriers to diabetes medication adherence using the Information-Motivation-
429 Behavioral Skills Model. *Diabetes Res Clin Pract* 2018; 142: 374-84.
- 430 32. To KW, Lee FKI. The effect of a theory-driven educational-intervention for improving
431 adherence to inhalation therapy in patients with chronic obstructive pulmonary disease: A
432 pilot study. Presented in *Hong Kong College of Gerontology Nursing Scientific Meeting*
433 *cum AGM 2018*. Hong Kong: Hong Kong College of Gerontology Nursing, 26 May
434 2018.
- 435 33. Blankenburg T, Benthin C, Pohl S, Bramer A, Kalbitz F, Lautenschlager C, Schutte W.
436 Survival of hypercapnic patients with COPD and obesity hypoventilation syndrome
437 treated with high intensity non-invasive ventilation in the daily routine care. *The Open*
438 *Respir Med J* 2017; 11: 31-40.
- 439 34. Tsai P, Wang S, Wang M, Su C, Yang T, Huang C, Fang S. Psychometric evaluation of
440 the Chinese version of the Pittsburgh Sleep Quality Index (CPSQI) in primary insomnia
441 and control subjects. *Quality of Life* 2005; 14(8): 1943-52.
- 442 35. Ho RTH, Fong TCT. Factor structure of the Chinese version of the Pittsburgh Sleep
443 Quality Index in breast cancer patients. *Sleep Med* 2014; 15: 565-9.
- 444 36. Cheung LM, Wong WS. The effects of insomnia and internet addiction on depression in
445 Hong Kong adolescents: an exploratory cross-sectional analysis. *J Sleep Res* 2010; 20(2).
446 <https://doi.org/10.1111/j.1365-2869.2010.00883.x>
- 447 37. Wong WS, Fielding R. Prevalence of insomnia among Chinese adults in Hong Kong: a
448 population-based study. *J Sleep Res* 2011; 20(1). [https://doi.org/10.1111/j.1365-](https://doi.org/10.1111/j.1365-2869.2010.00822.x)
449 [2869.2010.00822.x](https://doi.org/10.1111/j.1365-2869.2010.00822.x)

- 450 38. Chen R, Guan L, Wu W, Yang Z, Li X, Lui Q, et al. The Chinese version of the Severe
451 Respiratory Insufficiency questionnaire for patients with chronic hypercapnic chronic
452 obstructive pulmonary disease receiving non-invasive positive pressure ventilation. *BMJ*
453 *Open* 2017; 7:e017712. doi:10.1136/bmjopen-2017-017712
- 454 39. Kee JL. *Laboratory and diagnostic tests with nursing implications*, 6th ed.. Upper Saddle
455 River, New Jersey: Prentice Hall, 2002.
- 456 40. Malatesha G, Singh NK, Bharija A, Rehani B, Goel A. Comparison of arterial and
457 venous pH, bicarbonate, Pco2 and Po2 in initial emergency department assessment.
458 *Emerg Med J* 2007; 24(8): 569–71. doi: 10.1136/emj.2007.046979
- 459 41. Singer JD, Willett JB. *Applied longitudinal data analysis: modelling change and event*
460 *occurrence*. New York: Oxford University Press; 2003.
- 461 42. Little RJA: Missing-data adjustments in large surveys. *Journal of Business & Economic*
462 *Statistics* 1988; 6: 287-96.
- 463